Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

被引：67
作者：
Figueras-Aloy J. [1 ]
Manzoni P. [2 ]
Paes B. [3 ]
Simões E.A.F. [4 ]
Bont L. [5 ]
Checchia P.A. [6 ]
Fauroux B. [7 ]
Carbonell-Estrany X. [8 ]
机构：
[1] Hospital Clínic, Catedràtic de Pediatria, Universitat de Barcelona, Barcelona
[2] Sant’Anna Hospital, Turin
[3] Department of Paediatrics (Neonatal Division), McMaster University, Hamilton
[4] University of Colorado School of Medicine, Aurora, CO
[5] University Medical Center Utrecht, Utrecht
[6] Baylor College of Medicine, Texas Children’s Hospital Houston, Texas
[7] Necker University Hospital and Paris 5 University, Paris
[8] Hospital Clinic, Institut d’Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona
来源：
Infectious Diseases and Therapy | 2016年 / 5卷 / 4期
关键词：
Burden; Gestational age; Hospitalization; Immunoprophylaxis; Preterm; Respiratory syncytial virus; Risk;
D O I：
10.1007/s40121-016-0130-1
中图分类号：
学科分类号：
摘要：
Introduction: The REGAL (RSV Evidence—a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This second publication covers the risk and burden of RSV infection in preterm infants born at <37 weeks’ gestational age (wGA) without chronic lung disease or congenital heart disease. Methods: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. Studies reporting data for hospital visits/admissions for RSV infection among preterm infants as well as studies reporting RSV-associated morbidity, mortality, and risk factors were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results: 2469 studies were identified of which 85 were included. Preterm infants, particularly those born at lower wGA, tended to have higher RSV hospitalization (RSVH) rates compared with otherwise healthy term infants (high SOE). RSVH rates ranged from ~5 per 1000 children to >100 per 1000 children with the highest rates shown in the lowest gestational age infants (high SOE). Independent risk factors associated with RSVH include: proximity of birth to the RSV season, living with school-age siblings, smoking of mother during pregnancy or infant exposure to environmental smoking, reduced breast feeding, male sex, and familial atopy (asthma) (high SOE). Predictive models can identify 32/33–35 wGA infants at risk of RSVH (high SOE). Conclusion: RSV infection remains a major burden on Western healthcare systems and is associated with significant morbidity. Further studies focusing on the prevalence and burden of RSV in different gestational age cohorts, the changing risk of RSVH during the first year of life, and on RSV-related mortality in preterm infants are needed to determine the true burden of disease. Funding: AbbVie. © 2016, The Author(s).
引用
收藏
页码：417 / 452
页数：35
相关论文
共 103 条
  • [1] Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., Et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet, 375, pp. 1545-1555, (2010)
  • [2] Glezen W.P., Taber L.H., Frank A.L., Kasel J.A., Risk of primary infection and reinfection with respiratory syncytial virus, Am J Dis Child, 140, pp. 543-546, (1986)
  • [3] Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., Et al., The burden of respiratory syncytial virus infection in young children, N Engl J Med, 360, pp. 588-598, (2009)
  • [4] Hall C.B., Weinberg G.A., Blumkin A.K., Edwards K.M., Staat M.A., Schultz A.F., Et al., Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age, Pediatrics, 132, pp. e341-e348, (2013)
  • [5] Boyce T.G., Mellen B.G., Mitchel E.F., Wright P.F., Griffin M.R., Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid, J Pediatr, 137, pp. 865-870, (2000)
  • [6] Resch B., Respiratory syncytial virus infection in high-risk infants—an update on palivizumab prophylaxis, Open Microbiol J., 11, pp. 71-77, (2014)
  • [7] Figueras-Aloy J., Carbonell-Estrany X., Quero J., Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain, Pediatr Infect Dis J., 23, pp. 815-820, (2004)
  • [8] Figueras-Aloy J., Carbonell-Estrany X., Quero-Jimenez J., Fernandez-Colomer B., Guzman-Cabanas J., Echaniz-Urcelay I., Et al., FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks, Pediatr Infect Dis J., 27, pp. 788-793, (2008)
  • [9] Law B.J., Langley J.M., Allen U., Paes B., Lee D.S.C., Mitchell M., Et al., The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation, Pediatr Infect Dis J., 23, pp. 806-814, (2004)
  • [10] Blanken M.O., Koffijberg H., Nibbelke E.E., Rovers M.M., Bont L., on behalf of the Dutch RSV Neonatal Network, Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study, PLoS One, 8, (2013)
12345678910